Study (year) | Patient group (n) | Time frame (years) | Gene variants examined | OR (unadjusted) | OR (adjusted) | Comment |
---|---|---|---|---|---|---|
[4] (2008) | African American (515) and Caucasian (232) | March 2004 to August 2006; 2 centers | IL-1ra: absent A1 allele | MV 8.6% vs no-MV 2.6% (P = 0.003) | OR 2.65, P = 0.046 | To predict MV (n = 96). Not statistically significant if African Americans and Caucasians analyzed separately |
ARDS 9.1% vs no-ARDS 2.9%, P = 0.023 | OR 3.10, P = 0.052 | To predict ARDS (n = 49) | ||||
[5] (2010) | African American (443) | Not stated | 4 MYLK SNPs | P = 0.39 to 1.0 | - | To predict MV (n = 41) and ARDS (n = 28) |
Caucasian (253) | Not stated | 5 MYLK SNPs | P = 0.26 to 1.0 | - | To predict MV (n = 33) and ARDS (n = 19) | |
[6] (2011) | African American (395) | March 2004 to August 2006; 2 centers | 7 SP-B SNPs rs1130866 rs3024793 | P = 0.016 P = 0.030 | OR 2.27, P = 0.040 OR 3.00, P = 0.012 | To predict MV (n = 37) Not statistically significant if adjust for bacterial culture positive |
rs7316 | P = 0.06 | OR 2.95, P = 0.031 | To predict ARDS (n = 26) | |||
[3] (2012) | African American (474) | Not stated; 3 centers | CFTR 2 low risk vs 1 or 2 high risk [(TG)≥12T≤5] alleles | P = 0.0013 | OR 3.19, P = 0.0007 | To predict MV (n = 43) |
P = 0.0061 | OR 3.36, P = 0.0032 | To predict ARDS (n = 29). Nasal swab was done in 113 and positive for a virus in 43 (38%) | ||||
Caucasian (304) | Not stated; 3 centers | As above | P = 0.21 | Not statistically significant | To predict MV (n = 42) | |
P = 0.84 | Not statistically significant | To predict ARDS (n = 32). Nasal swab was done in 89 and positive for a virus in 22 (25%) | ||||
[7] (2014) | African American (443) | Not stated; 3 centers | Caspase-12 long allele | P = 0.83 and 0.48 | - | For MV (n = 41), ARDS (n = 28). Also reported for: mortality (n = 5), severe sepsis (n = 17), vasopressor use (n = 15), renal dysfunction (n = 11), hematologic dysfunction (n = 9) |
[2] (2016) | African American (474) | Not stated; 3 centers | Splicing factors of CFTR mRNA (7 genes, 66 SNPs) | 19 SNPs in 6 genes with P < 0.20 | 3 SNPs in CELF-2 (OR 2.95, 4.28, and 2.66 with P = 0.032, 0.004, and 0.044). 2 SNPs in TIA-1 (OR 3.70, 5.42 with P = 0.005, 0.018) | ARDS (n = 29). Also (TG)≥12T≤5 allele (OR 3.01, P = 0.012) and age ≥11 years (OR 14.9, P < 0.0001) |
Caucasian (304) | Not stated; 3 centers | 7 genes, 41 SNPs | 8 SNPs in 4 genes with P < 0.20 | 1 (different) SNP in CELF-2 (OR 3.22, P = 0.014). No TIA-1 SNPs or (TG)≥12T≤5 alleles | ARDS (n = 32). Also age ≥11 years (OR 9.20, P < 0.0001) and asthma (OR 0.20, P = 0.04) |